| Literature DB >> 35615415 |
Lucy Robertson1,2, Filipa Machado3,4,2, Sebastian Rutkowski5,2, Liliana Silva6,7,2, Sabina Miranda8,2, Ingeborg Farver-Vestergaard9,2, Thomas Janssens10,2, Karl P Sylvester11, Chris Burtin4, Andreja Šajnić12, Joana Cruz13.
Abstract
This paper provides an overview of some of the most memorable sessions that were (co)organised by the Allied Respiratory Professionals Assembly during the 2021 European Respiratory Society International Congress, which was held online for the second consecutive year due to the COVID-19 pandemic. Early Career Members from Assembly 9 summarised the content of the sessions (three oral communication sessions, two symposia and one Expert View) with the support of the chairs from the four Assembly groups: Respiratory Function Technologists and Scientists (Group 9.01); Physiotherapists (Group 9.02); Nurses (Group 9.03); and Psychologists and Behavioural Scientists (Group 9.04). The sessions covered the following topics: impact of COVID-19 on lung function and healthcare services, and the importance of quality assurance and technology in lung function assessment; diagnosis and management of sarcopenia in patients with chronic respiratory disease; maintenance of the effects of pulmonary rehabilitation; solutions outside the hospital for the management of patients with COVID-19 in need of health care; the nursing perspective during the COVID-19 pandemic; and psychological and behavioural issues in respiratory care. This highlights article provides valuable insight into the latest scientific data and emerging areas affecting clinical practice of allied respiratory professionals.Entities:
Year: 2022 PMID: 35615415 PMCID: PMC9125039 DOI: 10.1183/23120541.00674-2021
Source DB: PubMed Journal: ERJ Open Res ISSN: 2312-0541
FIGURE 1Classification of airway hyperresponsiveness (AHR) according to the European Respiratory Society 2017 technical standard [5]. Lab: laboratory. Reproduced and modified from [4] with permission from the authors.
Current definitions of sarcopenia
|
|
|
| |
|
| Low muscle strength | ||
|
| Low muscle strength + low muscle quantity/quality | Low muscle strength + low muscle quantity/quality | Low muscle strength + low physical performance |
|
| Low muscle strength + low muscle quantity/quality + low physical performance | ||
|
| Age-related, with no other evident specific cause | Age-related, with no other evident specific cause | |
|
| Secondary to a systemic disease ( | Secondary to a systemic disease ( |
EWGSOP: European Working Group in Sarcopenia in Older People; SCWD: Society of Sarcopenia, Cachexia and Wasting Disorders; SDOC: Sarcopenia Definition and Outcomes Consortium.